R
Rachel Neuwirth
Researcher at Takeda Pharmaceutical Company
Publications - 21
Citations - 589
Rachel Neuwirth is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Bortezomib & Fulvestrant. The author has an hindex of 11, co-authored 21 publications receiving 446 citations.
Papers
More filters
Journal ArticleDOI
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy
George Mulligan,David I. Lichter,Alessandra Di Bacco,Stephen J. Blakemore,Allison Berger,Erik Koenig,Hugues Bernard,William L. Trepicchio,Bin Li,Rachel Neuwirth,Nibedita Chattopadhyay,Joseph B. Bolen,Andrew Dorner,Helgi van de Velde,Deborah Ricci,Sundar Jagannath,James R. Berenson,Paul G. Richardson,Edward A. Stadtmauer,Robert Z. Orlowski,Sagar Lonial,Kenneth C. Anderson,Pieter Sonneveld,Jeśus F.San Miguel,Dixie Lee Esseltine,Matthew Schu +25 more
TL;DR: A significant clinical impact of NRAS mutation in myeloma is identified and a clear example of functional differences between the KRAS and NRAS oncogenes is demonstrated.
Journal ArticleDOI
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Irene M. Ghobrial,David S. Siegel,Ravi Vij,Jesus G. Berdeja,Paul G. Richardson,Rachel Neuwirth,Chirag Patel,F. Zohren,Jeffrey L. Wolf +8 more
TL;DR: This was the first clinical study to evaluate the safety, tolerability, maximal‐tolerated dose (MTD), dose‐limiting toxicity (DLT), pharmacokinetics, and preliminary clinical activity of TAK‐228, an oral TORC1/2 inhibitor, in patients with MM, NHL, or WM.
Journal ArticleDOI
Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
Patricia LoRusso,Karthik Venkatakrishnan,Ramesh K. Ramanathan,John Sarantopoulos,Daniel Mulkerin,Stephen Shibata,Anne Hamilton,Afshin Dowlati,Sridhar Mani,Michelle A. Rudek,Chris H. Takimoto,Rachel Neuwirth,Dixie Lee Esseltine,Percy Ivy +13 more
TL;DR: Patients with mild hepatic impairment do not require a starting dose adjustment of bortezomib and should be started at a reduced dose of 0.7 mg/m2, according to dosing recommendations in these special populations.
Journal ArticleDOI
Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.
TL;DR: Investigational oligopeptide analog of the fully active 10-amino acid C terminus of kisspeptin-54 reduces T and resulted in sustained T suppression in healthy males and in patients with prostate cancer.
Journal ArticleDOI
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Martin H. Voss,Michael S. Gordon,Monica M. Mita,Brian I. Rini,Vicky Makker,Teresa Macarulla,David Smith,Andrés Cervantes,Igor Puzanov,Roberto Pili,Ding Wang,Shadia I. Jalal,Shubham Pant,Manish R. Patel,Rachel Neuwirth,A. Enke,Yaping Shou,Farhad Sedarati,Douglas V. Faller,Howard A. Burris +19 more
TL;DR: Sapanisertib demonstrated a manageable safety profile, with preliminary antitumour activity observed in RCC and endometrial cancer, and pharmacodynamic findings demonstrated treatment-related reductions in TORC1/2 biomarkers.